Year: 2023

Tyson Foods Reports Fourth Quarter and Fiscal 2023 Results

Written by Customer Service on November 13, 2023. Posted in Earnings Releases And Operating Results.

Tyson Foods Sees Another Quarter of Sequential Adjusted Operating Income Growth with Continued Focus on Operational Excellence SPRINGDALE, Ark., Nov. 13, 2023 (GLOBE NEWSWIRE) — Tyson Foods, Inc. (NYSE: TSN), one of the world’s largest food companies and a recognized leader in protein with leading brands including Tyson, Jimmy Dean, Hillshire Farm, Ball Park, Wright, Aidells, ibp and State Fair, reported the following results:(in millions, except per share data) Fourth Quarter Twelve Months Ended 2023 2022 2023 2022Sales $ 13,348 $ 13,737 $ 52,881 $ 53,282 Operating Income (Loss) $ (463 ) $ 766 $ (395 ) $ 4,410Adjusted1 Operating Income (non-GAAP) $ 236 $ 823 $ 933 $ 4,414 Net Income (Loss) Per Share Attributable to Tyson $ (1.31 ) $ 1.50 $ (1.87 ) $ 8.92Adjusted1...

R1 RCM to Restate Certain Previously Issued Financial Statements Due to Errors in Accounting for Expenses Associated with Historical Acquisitions

Written by Customer Service on November 13, 2023. Posted in Earnings Releases And Operating Results.

No Material Impact on 2023 Financial Results; Reaffirms 2023 Outlook No Impact on Cash or Business Operations MURRAY, Utah, Nov. 13, 2023 (GLOBE NEWSWIRE) — R1 RCM Inc. (NASDAQ: RCM) (“R1”), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced its decision to restate its previously issued financial statements for the years ended December 31, 2022 and 2021 and interim periods, as well as for the first two quarters of 2023. Immediately prior to the scheduled filing of its Form 10-Q for the third quarter 2023, R1 identified errors related to the accounting for certain acquiree compensation costs (e.g., transaction bonuses and accelerated equity award vesting) incurred as a result of historical acquisitions. These expenses should have...

Intuitive Machines Reports Third Quarter 2023 Financial Results and Reaffirms Expected Launch of First Lunar Mission

Written by Customer Service on November 13, 2023. Posted in Earnings Releases And Operating Results.

Secured multi-day launch window for first lunar mission, beginning January 12, 2024 Selected by an International Space Agency in November for a $16.8 million contract to provide lunar rover services – the largest international award to date as the Company expands its global partnerships Diversified customer base with the first significant Department of Defense, Air Force Research Laboratory (“AFRL”) $9.5 million Joint Energy Technology Supplying On-Orbit Nuclear Power (JETSON) award Expanded operational capability with the new Lunar Production and Operations Center at the Houston Spaceport Began customer transition for NASA’s five-year $719 million Omnibus Multi-Engineering Services (“OMES”) III contract – revenue expected to begin in DecemberHOUSTON, Nov. 13, 2023 (GLOBE NEWSWIRE) — Intuitive Machines, Inc. (Nasdaq:...

Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Written by Customer Service on November 13, 2023. Posted in Earnings Releases And Operating Results.

– Conference Call Today at 8:30 a.m. ET – ATLANTA, Nov. 13, 2023 (GLOBE NEWSWIRE) — Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced financial results for the third quarter ended September 30, 2023. Key Highlights and Upcoming MilestonesHaving secured FDA guidance on our plan to progress IMC-1 to Phase 3 development to treat fibromyalgia (FM), we can convey that several life science companies are engaged and reviewing our Phase 2 data and proposed Phase 3 program as the basis for a potential forward development partnership. Submitted briefing materials to FDA concerning submission of a proposed investigational...

Celcuity Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

Written by Customer Service on November 13, 2023. Posted in Earnings Releases And Operating Results.

Received FDA clearance of IND to evaluate gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer (mCRPC)Entered into a clinical trial collaboration and supply agreement with Bayer AG to provide Nubeqa® (darolutamide) for planned Phase 1b/2 clinical trial Raised $50 million in private placement sale of equity Management to host webcast and conference call today, November 13, 2023, at 8:00 a.m. ETMINNEAPOLIS, Nov. 13, 2023 (GLOBE NEWSWIRE) — Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today reported financial results for the third quarter ended September 30, 2023 and provided other recent corporate updates. “Despite the important role the PI3K/mTOR pathway plays in tumor types such as breast...

Fortrea Reports Third Quarter 2023 Results

Written by Customer Service on November 13, 2023. Posted in Earnings Releases And Operating Results.

For the three months ended September 30, 2023:Revenues of $776.4 million GAAP net loss of $13.1 million Adjusted EBITDA of $70.5 million GAAP and adjusted diluted earnings (loss) per share of ($0.15) and $0.24, respectively Quarterly book-to-bill ratio of 1.24xDURHAM, N.C., Nov. 13, 2023 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today reported financial results for the third quarter ended September 30, 2023. “Fortrea delivered for its customers and executed against its priorities with discipline in its first quarter as an independent company,” said Tom Pike, chairman and CEO of Fortrea. “Customers are responding positively to the Fortrea team and the improvements we have made, as our normalizing book-to-bill ratio demonstrates. Our transformation continues...

Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting

Written by Customer Service on November 13, 2023. Posted in Public Companies.

– Data support the ongoing clinical development of TNG908 and TNG462 PRMT5 inhibitors for the treatment of MTAP-deleted cancers – BOSTON, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that two abstracts have been selected for poster presentations at the Society for Neuro-Oncology (SNO) 28th Annual Meeting taking place November 15-19, 2023, in Vancouver, Canada. “As we advance TNG908 and TNG462, our two MTA-cooperative PRMT5 inhibitors, in phase 1/2 clinical trials, we are pleased to share preclinical data at SNO that affirm their potential as new therapies for patients with MTAP-deleted cancers, including glioblastoma and malignant peripheral nerve sheath...

OTC Markets Group Welcomes Lithium Royalty Corp. to OTCQX

Written by Customer Service on November 13, 2023. Posted in Public Companies.

NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Lithium Royalty Corp. (TSX: LIRC; OTCQX: LITRF), a lithium-focused royalty company, has qualified to trade on the OTCQX® Best Market. Lithium Royalty Corp. upgraded to OTCQX from the Pink® market. Lithium Royalty Corp. begins trading today on OTCQX under the symbol “LITRF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com. Upgrading to the OTCQX Market is an important step for companies seeking to provide transparent trading for their U.S. investors. For companies listed on a qualified international exchange, streamlined market standards enable them to utilize their home market...

Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights

Written by Customer Service on November 13, 2023. Posted in Earnings Releases And Operating Results.

On track to present initial safety and biomarker data from three Cohort 1 patients in global Phase 1/2 upliFT-D trial of PBFT02 for the treatment of patients with frontotemporal dementia (FTD) with granulin mutations (GRN) in Q4 2023 Expect to report initial safety and biomarker data from Dose 3 patients in global Phase 1/2 Imagine-1 clinical trial for gangliosidosis (GM1) in mid-2024 Robust balance sheet to support achievement of meaningful clinical milestones, with cash runway into Q4 2025PHILADELPHIA, Nov. 13, 2023 (GLOBE NEWSWIRE) — Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today reported financial results for the third quarter ended September 30, 2023, and provided recent business highlights. “Our...

Edible Garden Reports 19.4% Year-Over-Year Revenue Growth for Third Quarter of 2023

Written by Customer Service on November 13, 2023. Posted in Earnings Releases And Operating Results.

Continues expansion of retail distribution network across the U.S. Pulp Line of Fermented Gourmet Sauces Expands to New York and St. Louis Markets with ‘Bland to Bold’ Flavors Self-Watering Display Promises to Revolutionize In-Store Plant Presentation Enhancing Infrastructure and Refining Data Analytics Aimed at Boosting Profit Margins Conference Call to Be Held Today at 8:00 AM ET BELVIDERE, N.J., Nov. 13, 2023 (GLOBE NEWSWIRE) — Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA), locally grown, organic, and sustainable produce and products, today provided a business update and reported financial results for the three months ended September 30, 2023. Mr. Jim Kras, Chief Executive Officer of Edible Garden, stated, “We are pleased...

Year: 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals